Moleculin Participates in Virtual Investor “What This Means” Segment

Core Insights - Moleculin Biotech, Inc. announced positive topline efficacy results from its U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases [3][5] - The trial was a multi-center, open-label, single-arm study that determined the Maximum Tolerable Dose and Recommended Phase 2 Dose, and explored the efficacy of Annamycin as a single agent [3][5] - Annamycin is designed to avoid multidrug resistance mechanisms and lacks the cardiotoxicity common with currently prescribed anthracyclines, making it a promising candidate for treating relapsed or refractory acute myeloid leukemia and STS lung metastases [5][6] Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [2][5] - The company is advancing a pipeline that includes Annamycin and WP1066, an Immune/Transcription Modulator targeting various cancers [7] - The company has initiated the MIRACLE Trial, a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia [6]